Novel ferrocene-containing triacyl derivative of resveratrol improves viability parameters in ovary cells.

Besides the use of resveratrol as a drug candidate, there are obstacles mainly due to its poor pharmacokinetic properties. Numerous studies are being conducted on the synthesis of resveratrol derivatives that exhibit enhanced biological activity. The aim of our research was to investigate activity of the newly synthesized ferrocene-containing triacyl derivative of resveratrol to achieve cell protection from endo/exogenous ROS and reduction in cell death by assessing multiple endpoints. Our research showed that both resveratrol and the resveratrol derivative (1-100 μM) lower the levels of ROS in CHO-K1 cells. Resveratrol at doses < 20 μM had little or no effect on cell proliferation, while at higher doses a significant inhibitory effect on cell proliferation and viability has been noticed. The activity of the new derivative was significantly altered compared to resveratrol - cellular viability was not suppressed regardless of the concentration applied, and the extent of apoptosis was low. In summary, the new ferrocene-resveratrol derivative has the potential to protect cells from oxidative stress due to its low cytotoxicity and retained antioxidant properties, whereas caution should be exercised with resveratrol at higher doses as it significantly impairs cell viability and induces cell death. By linking ROS to specific diseases (relevance in neurodegenerative, cardiovascular, neoplastic diseases), we can assume that the new resveratrol derivative can prevent or alleviate the mentioned disorders. Furthermore, recognition of the resveratrol derivative as an anti-apoptotic chemical could be useful in the cultivation of various cell lines on a large scale in the industrial biotechnology.